(1-azinone)-substituted pyridoindoles

Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R 1 is H or optionally substituted alkyl; R 2 , R 3 , R 4 are each independently selected from H, -O-alkyl, -S-alkyl, alkyl, halo, -CF 3 , and -CN; G is -CR 12 R 13 -NR 5 - or -NR 5 -CR 12 R 13 ; R 5 is H, optionally substituted alkyl, optionally substituted heterocycle, -C(=O)-R 6 , -C(=O)-O-R 7 , or -C(=O)-NR 19 R 20 ; R 6 and R 7 are each optionally substituted alkyl or optionally substituted heterocycle; R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 19 and R 20 are each independently selected from H or optionally substituted alkyl; R 14 and R 15 are each independently H or halogen; Y is CH or N; L is -CH 2 -O-, -CH 2 CH 2 -, -CH=CH- or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.